These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9925736)

  • 1. Vasopeptidase inhibitors: incorporation of geminal and spirocyclic substituted azepinones in mercaptoacyl dipeptides.
    Robl JA; Sulsky R; Sieber-McMaster E; Ryono DE; Cimarusti MP; Simpkins LM; Karanewsky DS; Chao S; Asaad MM; Seymour AA; Fox M; Smith PL; Trippodo NC
    J Med Chem; 1999 Jan; 42(2):305-11. PubMed ID: 9925736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual metalloprotease inhibitors. 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors.
    Robl JA; Cimarusti MP; Simpkins LM; Brown B; Ryono DE; Bird JE; Asaad MM; Schaeffer TR; Trippodo NC
    J Med Chem; 1996 Jan; 39(2):494-502. PubMed ID: 8558518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
    Fink CA; Carlson JE; McTaggart PA; Qiao Y; Webb R; Chatelain R; Jeng AY; Trapani AJ
    J Med Chem; 1996 Aug; 39(16):3158-68. PubMed ID: 8759637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.
    Fournie-Zaluski MC; Coric P; Thery V; Gonzalez W; Meudal H; Turcaud S; Michel JB; Roques BP
    J Med Chem; 1996 Jun; 39(13):2594-608. PubMed ID: 8691458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
    Robl JA; Sun CQ; Stevenson J; Ryono DE; Simpkins LM; Cimarusti MP; Dejneka T; Slusarchyk WA; Chao S; Stratton L; Misra RN; Bednarz MS; Asaad MM; Cheung HS; Abboa-Offei BE; Smith PL; Mathers PD; Fox M; Schaeffer TR; Seymour AA; Trippodo NC
    J Med Chem; 1997 May; 40(11):1570-7. PubMed ID: 9171867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New alpha-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11.
    Fink CA; Qiao Y; Berry CJ; Sakane Y; Ghai RD; Trapani AJ
    J Med Chem; 1995 Dec; 38(26):5023-30. PubMed ID: 8544178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A computational approach to the study of the binding mode of dual ACE/NEP inhibitors.
    Dimitropoulos N; Papakyriakou A; Dalkas GA; Sturrock ED; Spyroulias GA
    J Chem Inf Model; 2010 Mar; 50(3):388-96. PubMed ID: 20170101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening of selected basidiomycetes for inhibitory activity on neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE).
    Melzig MF; Pieper S; Siems WE; Heder G; Bóttger A; Liberra K; Lindequist U
    Pharmazie; 1996 Jul; 51(7):501-3. PubMed ID: 8774843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.
    Coric P; Turcaud S; Meudal H; Roques BP; Fournie-Zaluski MC
    J Med Chem; 1996 Mar; 39(6):1210-9. PubMed ID: 8632427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
    Duncan AM; James GM; Anastasopoulos F; Kladis A; Briscoe TA; Campbell DJ
    J Pharmacol Exp Ther; 1999 Apr; 289(1):295-303. PubMed ID: 10087017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin I-converting enzyme-dependent and neutral endopeptidase-dependent generation and degradation of angiotensin II contrarily modulate noradrenaline release: implications for vasopeptidase-inhibitor therapy?
    Raasch W; Dominiak P; Dendorfer A
    J Hypertens; 2005 Aug; 23(8):1597-604. PubMed ID: 16003188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential tissue and enzyme inhibitory effects of the vasopeptidase inhibitor omapatrilat in the rat.
    Kubota E; Dean RG; Hubner RA; Casley DJ; Johnston CI; Burrell LM
    Clin Sci (Lond); 2003 Sep; 105(3):339-45. PubMed ID: 12741953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors.
    Olimpieri F; Tambaro S; Fustero S; Lazzari P; Sanchez-Roselló M; Pani L; Volonterio A; Zanda M
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4715-9. PubMed ID: 19596577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasopeptidase inhibitors, neutral endopeptidase inhibitors, and dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
    Nawarskas J; Rajan V; Frishman WH
    Heart Dis; 2001; 3(6):378-85. PubMed ID: 11975822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat.
    Hubner RA; Kubota E; Casley DJ; Johnston CI; Burrell LM
    J Hypertens; 2001 May; 19(5):941-6. PubMed ID: 11393678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat.
    Sulpizio AC; Pullen MA; Edwards RM; Brooks DP
    J Pharmacol Exp Ther; 2004 Jun; 309(3):1141-7. PubMed ID: 14769834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasopeptidase inhibition: a double-edged sword?
    Campbell DJ
    Hypertension; 2003 Mar; 41(3):383-9. PubMed ID: 12623931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240.
    Pfister M; Martin NE; Haskell LP; Barrett JS
    J Clin Pharmacol; 2004 Jun; 44(6):621-31. PubMed ID: 15145970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasopeptidase inhibitors.
    Sagnella GA
    J Renin Angiotensin Aldosterone Syst; 2002 Jun; 3(2):90-5. PubMed ID: 12228848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.